Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia

Laurence C. Cheung; Mark N. Cruickshank; Anastasia M. Hughes; Sajla Singh; Grace-Alyssa Chua; Jette Ford; Emanuela Ferrari; Joyce Oommen; Sebastien Malinge; Richard B. Lock; Ursula R. Kees; Rishi S. Kotecha

doi:10.3324/haematol.2018.192906

Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia

Laurence C. Cheung, Mark N. Cruickshank, Anastasia M. Hughes, Sajla Singh, Grace-Alyssa Chua, Jette Ford, Emanuela Ferrari, Joyce Oommen, Sebastien Malinge, Richard B. Lock, Ursula R. Kees, Rishi S. Kotecha

Research output: Contribution to journal › Letter

2 Citations (Scopus)

Original language	English
Number of pages	4
Journal	Haematologica
Volume	104
Issue number	7
DOIs	https://doi.org/10.3324/haematol.2018.192906
Publication status	Published - 30 Jun 2019

Access to Document

10.3324/haematol.2018.192906

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601077/

1 Active

Combinatorial therapeutics in high-risk infant acute lymphoblastic leukaemia
Kotecha, R.
National Health & Medical Research Council NHMRC
1/01/18 → 31/12/21
Project: Research

Cite this

Cheung, L. C., Cruickshank, M. N., Hughes, A. M., Singh, S., Chua, G-A., Ford, J., Ferrari, E., Oommen, J., Malinge, S., Lock, R. B., Kees, U. R., & Kotecha, R. S. (2019). Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia. Haematologica, 104(7). https://doi.org/10.3324/haematol.2018.192906

Cheung, Laurence C. ; Cruickshank, Mark N. ; Hughes, Anastasia M. ; Singh, Sajla ; Chua, Grace-Alyssa ; Ford, Jette ; Ferrari, Emanuela ; Oommen, Joyce ; Malinge, Sebastien ; Lock, Richard B. ; Kees, Ursula R. ; Kotecha, Rishi S. / Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia. In: Haematologica. 2019 ; Vol. 104, No. 7.

@article{d07400968a3a4bada7ebdfc3d93ba3a5,

title = "Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia",

author = "Cheung, {Laurence C.} and Cruickshank, {Mark N.} and Hughes, {Anastasia M.} and Sajla Singh and Grace-Alyssa Chua and Jette Ford and Emanuela Ferrari and Joyce Oommen and Sebastien Malinge and Lock, {Richard B.} and Kees, {Ursula R.} and Kotecha, {Rishi S.}",

year = "2019",

month = jun,

day = "30",

doi = "10.3324/haematol.2018.192906",

language = "English",

volume = "104",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "7",

}

Cheung, LC, Cruickshank, MN, Hughes, AM, Singh, S, Chua, G-A, Ford, J, Ferrari, E, Oommen, J, Malinge, S, Lock, RB, Kees, UR & Kotecha, RS 2019, 'Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia', Haematologica, vol. 104, no. 7. https://doi.org/10.3324/haematol.2018.192906

Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia. / Cheung, Laurence C.; Cruickshank, Mark N.; Hughes, Anastasia M.; Singh, Sajla; Chua, Grace-Alyssa; Ford, Jette; Ferrari, Emanuela; Oommen, Joyce; Malinge, Sebastien; Lock, Richard B.; Kees, Ursula R.; Kotecha, Rishi S.

In: Haematologica, Vol. 104, No. 7, 30.06.2019.

Research output: Contribution to journal › Letter

TY - JOUR

T1 - Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia

AU - Cheung, Laurence C.

AU - Cruickshank, Mark N.

AU - Hughes, Anastasia M.

AU - Singh, Sajla

AU - Chua, Grace-Alyssa

AU - Ford, Jette

AU - Ferrari, Emanuela

AU - Oommen, Joyce

AU - Malinge, Sebastien

AU - Lock, Richard B.

AU - Kees, Ursula R.

AU - Kotecha, Rishi S.

PY - 2019/6/30

Y1 - 2019/6/30

U2 - 10.3324/haematol.2018.192906

DO - 10.3324/haematol.2018.192906

M3 - Letter

C2 - 30679330

VL - 104

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 7

ER -

Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia

Access to Document

Projects

Combinatorial therapeutics in high-risk infant acute lymphoblastic leukaemia

Cite this